This survey is the first of its kind in Korea to determine a representative COVID-19 antibody prevalence rate by systematically and cost-effectively surveying many people within a short period (about 3 weeks)

This survey is the first of its kind in Korea to determine a representative COVID-19 antibody prevalence rate by systematically and cost-effectively surveying many people within a short period (about 3 weeks). and anti-N were 97.6% and 57.1%, respectively. Since the Korea Disease Control and Prevention Agency offers reported a cumulative incidence of confirmed instances of 37.8% through July 31, 2022, the proportion of unreported infections among all COVID-19 infection was suggested to be 33.9%. == CONCLUSIONS == The K-SEROSMART represents the first nationwide, community-based seroepidemiologic survey of COVID-19, confirming that most individuals possess antibodies to SARS-CoV-2 and that a significant number of unreported instances existed. Furthermore, this study lays the foundation for a monitoring system to continually monitor transmission at the community level and the response to COVID-19. Keywords:COVID-19, Seroepidemiologic studies, Antibody, Community Health Survey, Sampling studies == GRAPHICAL ABSTRACT == == Intro == On March 11, 2020, the entire world Health Organization declared coronavirus disease 2019 (COVID-19) a global pandemic [1]. As of July 31, 2022, over 580 million confirmed instances of COVID-19 have been reported worldwide, resulting in approximately 6.42 million deaths. In Korea, community outbreak offers persisted since the emergence of COVID-19 (Number 1), with over 19.77 million confirmed cases and more than 25,000 deaths reported [2]. == Number 1. == Epidemic Pax1 curve of coronavirus disease 2019 (COVID-19) in Korea from January 20, 2020 to September 30, 2022. In Korea, the test-trace-isolate-quarantine (TTIQ) containment strategy has been employed since the beginning of the COVID-19 pandemic in 2020 to promptly identify infected individuals and disrupt transmission routes through quick testing and considerable follow-up [3]. However, in late 2020, the third maximum of COVID-19 occurred. From then onward, the proportion of instances with epidemiologic transmission routes unknown at the time of analysis improved, resulting CCT241533 hydrochloride in many unreported instances within the community [4]. These instances have been reported to account for 5% to 80% of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inside a systematic review and meta-analysis worldwide [5], who shed the computer virus at similar levels comparable to symptomatic individuals [6,7]. Although they do not require medical care, these instances contribute to the spread of the disease within the community [8]. THE ENTIRE WORLD Health Business recommends population-based seroepidemiologic studies to determine the prevalence of antibodies to SARS-CoV-2, including asymptomatic infections in the community [9]. Seroepidemiologic studies of COVID-19 can be used to monitor and assess the level of immunity to the virus inside a populace by directly measuring the presence of antibodies resulting from natural illness or vaccination [10-12]. Serotracking data reveals that as of November 2022, a total of 3,924 seroprevalence studies for COVID-19 have been carried out in 140 countries worldwide [13]. A meta-analysis based on some of these serotracker data, excluding studies with incorrect sample frames and methodological shortcomings, shows that population-based estimations of COVID-19 much exceed reported instances. The study emphasizes the importance of conducting high-quality and standardized collaborative serosurveillance through random sampling to monitor the COVID-19 pandemic and prepare for potential emerging viruses in the future [14]. The United Kingdom adopted a random sampling approach, surveying 150,000 people every month for 23 weeks starting from May 2020, during the early phase of the pandemic. The Real-time Assessment of Community CCT241533 hydrochloride Transmission Study produced community-based data on antibody-positive rates repeatedly. This data serves as the basis for understanding the spread of CCT241533 hydrochloride the pandemic and creating effective quarantine response strategies [15]. The COVID-19 Serosurveillance Network in Australia regularly calculates the seroprevalence of COVID-19 using residual blood from donors aged 18 years and older [16]. In the United States, the prevalence of anti-nucleocapsid proteins of SARS-CoV-2 was reported every 4 weeks from September 2021 to April 2022 using blood samples collected at healthcare facilities for clinical tests [17]. Additionally, extra data within the seroepidemiology of COVID-19 were collected in the 2021-2022 National Health and Nourishment Examination Survey to conquer the limitations of convenience sampling [18]. In Korea, several seroprevalence studies for COVID-19 have been conducted; however, most of these studies were small-scale and relied on convenience sampling. Furthermore, these studies did not provide analysis by region, age, or additional socio-demographic factors. The use of residual sample from other survey systems has been limited in CCT241533 hydrochloride calculating a representative prevalence of antibodies to SARS-CoV-2 [4,12,19,20]. The prevalence of antibodies to SARS-CoV-2 may.